Christopher Y. Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher Y. Lu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Jianlin Chen
Department of Internal Medicine (Nephrology), University of Texas Southwestern Medical Center, Dallas, Texas 75390-8856, USA
6 shared publications- Pamela D. Winterberg
Division of Pediatric Nephrology, Emory University School of Medicine, Atlanta, GA 30322, USA
5 shared publications Xin J. Zhou
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas
5 shared publicationsYanxia Wang
Department of Internal Medicine, Nephrology Division, University of Texas Southwestern Medical Center, Dallas, Texas
5 shared publicationsJohn R. Hartono
Department of Internal Medicine, Nephrology Division, University of Texas Southwestern Medical Center, Dallas, Texas
4 shared publicationsMichael Bennett
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
4 shared publications
Latest Publications
- 1 December 2015
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 26 (12) , 2893-2895
Oxidative Stress and Metabolism
- 1 December 2015
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 26 (12) , 2893-2895
Oxidative Stress and Metabolism
- Open Access
- 1 March 2014
- Published by Elsevier in Kidney International
- Vol. 85 (3) , 496-498
β-Lapachone ameliorates murine cisplatin nephrotoxicity: NAD + , NQO1, and SIRT1 at the crossroads of metabolism, injury, and inflammation
- 1 March 2014
- Published by Elsevier in Kidney International
- Vol. 85 (3) , 496-498
Open Accessβ-Lapachone ameliorates murine cisplatin nephrotoxicity: NAD + , NQO1, and SIRT1 at the crossroads of metabolism, injury, and inflammation
- 15 July 2013
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 305 (2) , F164-F172
Reactive oxygen species and IRF1 stimulate IFNα production by proximal tubules during ischemic AKI
We previously reported that expression of the transcription factor interferon regulatory factor 1 (IRF1) is an early, critical maladaptive signal expressed by renal tubules during murine ischemic acute kidney injury (AKI). We now show that IRF1 mediates signals from reactive oxygen species (ROS) generated during ischemic AKI and that these signals ultimately result in production of α-subtypes of type I interferons (IFNαs). We found that genetic knockout of the common type I IFN receptor (IFNARI−/−) improved kidney function and histology during AKI. There are major differences in the spatial-temporal production of the two major IFN subtypes, IFNβ and IFNαs: IFNβ expression peaks at 4 h, earlier than IFNαs, and continues at the same level at 24 h; expression of IFNαs also increases at 4 h but continues to increase through 24 h. The magnitude of the increase in IFNαs relative to baseline is much greater than that of IFNβ. We show by immunohistology and study of isolated cells that IFNβ is produced by renal leukocytes and IFNαs are produced by renal tubules. IRF1, IFNαs, and IFNARI were found on the same renal tubules during ischemic AKI. Furthermore, we found that ROS induced IFNα expression by renal tubules in vitro. This expression was inhibited by small interfering RNA knockdown of IRF1. Overexpression of IRF1 resulted in the production of IFNαs. Furthermore, we found that IFNα stimulated production of maladaptive proinflammatory CXCL2 by renal tubular cells. Altogether our data support the following autocrine pathway in renal tubular cells: ROS > IRF1 > IFNα > IFNARI > CXCL2.
- 15 July 2013
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 305 (2) , F164-F172
Reactive oxygen species and IRF1 stimulate IFNα production by proximal tubules during ischemic AKI
We previously reported that expression of the transcription factor interferon regulatory factor 1 (IRF1) is an early, critical maladaptive signal expressed by renal tubules during murine ischemic acute kidney injury (AKI). We now show that IRF1 mediates signals from reactive oxygen species (ROS) generated during ischemic AKI and that these signals ultimately result in production of α-subtypes of type I interferons (IFNαs). We found that genetic knockout of the common type I IFN receptor (IFNARI−/−) improved kidney function and histology during AKI. There are major differences in the spatial-temporal production of the two major IFN subtypes, IFNβ and IFNαs: IFNβ expression peaks at 4 h, earlier than IFNαs, and continues at the same level at 24 h; expression of IFNαs also increases at 4 h but continues to increase through 24 h. The magnitude of the increase in IFNαs relative to baseline is much greater than that of IFNβ. We show by immunohistology and study of isolated cells that IFNβ is produced by renal leukocytes and IFNαs are produced by renal tubules. IRF1, IFNαs, and IFNARI were found on the same renal tubules during ischemic AKI. Furthermore, we found that ROS induced IFNα expression by renal tubules in vitro. This expression was inhibited by small interfering RNA knockdown of IRF1. Overexpression of IRF1 resulted in the production of IFNαs. Furthermore, we found that IFNα stimulated production of maladaptive proinflammatory CXCL2 by renal tubular cells. Altogether our data support the following autocrine pathway in renal tubular cells: ROS > IRF1 > IFNα > IFNARI > CXCL2.
- 1 December 2012
- Published by Elsevier in Kidney International
- Vol. 82 (11) , 1195-1207
Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury
- 1 December 2012
- Published by Elsevier in Kidney International
- Vol. 82 (11) , 1195-1207
Endothelial pentraxin 3 contributes to murine ischemic acute kidney injury
- Open Access
- 28 October 2011
- Published by Springer Nature in Pediatric Nephrology
- Vol. 27 (10) , 1847-1854
Acute kidney injury: a conspiracy of toll-like receptor 4 on endothelia, leukocytes, and tubules
Ischemic acute kidney injury (AKI) contributes to considerable morbidity and mortality in hospitalized patients and can contribute to rejection during kidney transplantation. Maladaptive immune responses can exacerbate injury, and targeting these responses holds promise as therapy for AKI. In the last decade, a number of molecules and receptors were identified in the innate immune response to ischemia–reperfusion injury. This review primarily focuses on one pathway that leads to maladaptive inflammation: toll-like receptor 4 (TLR4) and one of its ligands, high mobility group box protein 1 (HMGB1). The temporal–spatial roles and potential therapeutics targeting this particular receptor–ligand interaction are also explored.
- 28 October 2011
- Published by Springer Nature in Pediatric Nephrology
- Vol. 27 (10) , 1847-1854
Open AccessAcute kidney injury: a conspiracy of toll-like receptor 4 on endothelia, leukocytes, and tubules
Ischemic acute kidney injury (AKI) contributes to considerable morbidity and mortality in hospitalized patients and can contribute to rejection during kidney transplantation. Maladaptive immune responses can exacerbate injury, and targeting these responses holds promise as therapy for AKI. In the last decade, a number of molecules and receptors were identified in the innate immune response to ischemia–reperfusion injury. This review primarily focuses on one pathway that leads to maladaptive inflammation: toll-like receptor 4 (TLR4) and one of its ligands, high mobility group box protein 1 (HMGB1). The temporal–spatial roles and potential therapeutics targeting this particular receptor–ligand interaction are also explored.
- Open Access
- 1 September 2011
- Published by Elsevier in Kidney International
- Vol. 80 (5) , 504-515
Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4
- 1 September 2011
- Published by Elsevier in Kidney International
- Vol. 80 (5) , 504-515
Open AccessEarly interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4
- Open Access
- 1 May 2011
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 300 (5) , F1180-F1192
Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1
Ischemic acute kidney injury (AKI) triggers expression of adaptive (protective) and maladaptive genes. Agents that increase expression of protective genes should provide a therapeutic benefit. We now report that bardoxolone methyl (BARD) ameliorates ischemic murine AKI as assessed by both renal function and pathology. BARD may exert its beneficial effect by increasing expression of genes previously shown to protect against ischemic AKI, NF-E2-related factor 2 (Nrf2), peroxisome proliferator-activated receptor-γ (PPARγ), and heme oxygenase 1 (HO-1). Although we found that BARD alone or ischemia-reperfusion alone increased expression of these genes, the greatest increase occurred after the combination of both ischemia-reperfusion and BARD. BARD had a different mode of action than other agents that regulate PPARγ and Nrf2. Thus we report that BARD regulates PPARγ, not by acting as a ligand but by increasing the amount of PPARγ mRNA and protein. This should increase ligand-independent effects of PPARγ. Similarly, BARD increased Nrf2 mRNA; this increased Nrf2 protein by mechanisms in addition to the prolongation of Nrf2 protein half-life previously reported. Finally, we localized expression of these protective genes after ischemia and BARD treatment. Using double-immunofluorescence staining for CD31 and Nrf2 or PPARγ, we found increased Nrf2 and PPARγ on glomerular endothelia in the cortex; Nrf2 was also present on cortical peritubular capillaries. In contrast, HO-1 was localized to different cells, i.e., tubules and interstitial leukocytes. Although Nrf2-dependent increases in HO-1 have been described, our data suggest that BARD's effects on tubular and leukocyte HO-1 during ischemic AKI may be Nrf2 independent. We also found that BARD ameliorated cisplatin nephrotoxicity.
- 1 May 2011
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 300 (5) , F1180-F1192
Open AccessBardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1
Ischemic acute kidney injury (AKI) triggers expression of adaptive (protective) and maladaptive genes. Agents that increase expression of protective genes should provide a therapeutic benefit. We now report that bardoxolone methyl (BARD) ameliorates ischemic murine AKI as assessed by both renal function and pathology. BARD may exert its beneficial effect by increasing expression of genes previously shown to protect against ischemic AKI, NF-E2-related factor 2 (Nrf2), peroxisome proliferator-activated receptor-γ (PPARγ), and heme oxygenase 1 (HO-1). Although we found that BARD alone or ischemia-reperfusion alone increased expression of these genes, the greatest increase occurred after the combination of both ischemia-reperfusion and BARD. BARD had a different mode of action than other agents that regulate PPARγ and Nrf2. Thus we report that BARD regulates PPARγ, not by acting as a ligand but by increasing the amount of PPARγ mRNA and protein. This should increase ligand-independent effects of PPARγ. Similarly, BARD increased Nrf2 mRNA; this increased Nrf2 protein by mechanisms in addition to the prolongation of Nrf2 protein half-life previously reported. Finally, we localized expression of these protective genes after ischemia and BARD treatment. Using double-immunofluorescence staining for CD31 and Nrf2 or PPARγ, we found increased Nrf2 and PPARγ on glomerular endothelia in the cortex; Nrf2 was also present on cortical peritubular capillaries. In contrast, HO-1 was localized to different cells, i.e., tubules and interstitial leukocytes. Although Nrf2-dependent increases in HO-1 have been described, our data suggest that BARD's effects on tubular and leukocyte HO-1 during ischemic AKI may be Nrf2 independent. We also found that BARD ameliorated cisplatin nephrotoxicity.
- Open Access
- 1 February 2011
- Published by Elsevier in Kidney International
- Vol. 79 (3) , 288-299
Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury
- 1 February 2011
- Published by Elsevier in Kidney International
- Vol. 79 (3) , 288-299
Open AccessToll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury
- 1 July 2009
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 20 (7) , 1544-1555
IRF-1 Promotes Inflammation Early after Ischemic Acute Kidney Injury
Acute renal ischemia elicits an inflammatory response that may exacerbate acute kidney injury, but the regulation of the initial signals that recruit leukocytes is not well understood. Here, we found that IFN regulatory factor 1 (IRF-1) was a critical, early proinflammatory signal released during ischemic injury in vitro and in vivo. Within 15 min of reperfusion, proximal tubular cells of the S3 segment produced IRF-1, which is a transcription factor that activates proinflammatory genes. Transgenic knockout of IRF-1 ameliorated the impairment of renal function, morphologic injury, and inflammation after acute ischemia. Bone marrow chimera experiments determined that maximal ischemic injury required IRF-1 expression by both leukocytes and radioresistant renal cells, the latter identified as S3 proximal tubule cells in the outer medulla by in situ hybridization and immunohistochemistry. In vitro, reactive oxygen species, generated during ischemia/reperfusion injury, stimulated expression of IRF-1 in an S3 proximal tubular cell line. Taken together, these data suggest that IRF-1 gene activation by reactive oxygen species is an early signal that promotes inflammation after ischemic renal injury.
- 1 July 2009
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 20 (7) , 1544-1555
IRF-1 Promotes Inflammation Early after Ischemic Acute Kidney Injury
Acute renal ischemia elicits an inflammatory response that may exacerbate acute kidney injury, but the regulation of the initial signals that recruit leukocytes is not well understood. Here, we found that IFN regulatory factor 1 (IRF-1) was a critical, early proinflammatory signal released during ischemic injury in vitro and in vivo. Within 15 min of reperfusion, proximal tubular cells of the S3 segment produced IRF-1, which is a transcription factor that activates proinflammatory genes. Transgenic knockout of IRF-1 ameliorated the impairment of renal function, morphologic injury, and inflammation after acute ischemia. Bone marrow chimera experiments determined that maximal ischemic injury required IRF-1 expression by both leukocytes and radioresistant renal cells, the latter identified as S3 proximal tubule cells in the outer medulla by in situ hybridization and immunohistochemistry. In vitro, reactive oxygen species, generated during ischemia/reperfusion injury, stimulated expression of IRF-1 in an S3 proximal tubular cell line. Taken together, these data suggest that IRF-1 gene activation by reactive oxygen species is an early signal that promotes inflammation after ischemic renal injury.
- 23 February 2009
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 133 (3) , i3
Essential and unique roles of PIP5K-γ and -α in Fcγ receptor-mediated phagocytosis
1. 1. Mao, 2. et al . 2009. J. Cell Biol. doi:10.1083/jcb.200806121. [OpenUrl][1][Abstract/FREE Full Text][2] [1]: {openurl}?query=rft_id%253Dinfo%253Adoi%252F10.1083%252Fjcb.200806121%26rft_id%253Dinfo%253Apmid%252F19153220%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%
- 23 February 2009
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 133 (3) , i3
Essential and unique roles of PIP5K-γ and -α in Fcγ receptor-mediated phagocytosis
1. 1. Mao, 2. et al . 2009. J. Cell Biol. doi:10.1083/jcb.200806121. [OpenUrl][1][Abstract/FREE Full Text][2] [1]: {openurl}?query=rft_id%253Dinfo%253Adoi%252F10.1083%252Fjcb.200806121%26rft_id%253Dinfo%253Apmid%252F19153220%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%